DR. STANLEY ISAAC RAPOPORT, MD
Osteopathic Medicine at 44 Pl, Washington, DC
License number
DC MD2741
Category
Osteopathic Medicine
Type
General Practice
Address
Address
3010 44Th Pl NW, Washington, DC 20016
Phone
(202) 966-7355
Personal information
See more information about STANLEY ISAAC RAPOPORT at radaris.comName
Address
Phone
3010 44Th Pl NW, Washington, DC 20016
Professional information
Dr. Stanley I Rapoport, Washington DC - MD (Doctor of Medicine)
Specialties:
Other
Address:
3010 44Th Pl NW SUITE WS, Washington 20016
(202) 966-7355 (Phone)
(202) 966-7355 (Phone)
Languages:
English
Education:
Medical School
Harvard Medical School
Graduated: 1959
Harvard Medical School
Graduated: 1959
Targeting Of Liposomes To The Blood-Brain Barrier
US Patent:
2002002, Feb 28, 2002
Filed:
Feb 26, 2001
Appl. No.:
09/794719
Inventors:
Michael Micklus - Philadelphia PA, US
Nigel Greig - Silver Spring MD, US
Stanley Rapoport - Washington DC, US
Nigel Greig - Silver Spring MD, US
Stanley Rapoport - Washington DC, US
International Classification:
A61K039/395, A61K009/127
US Classification:
424/130100, 424/450000
Abstract:
The present invention is directed to the targeting of drugs, peptides, and proteins to the brain. Liposomes containing the compound to be delivered are coupled to antibody binding fragments which bind to receptors on the vascular endothelium of the blood-brain barrier. The targeted receptors include transferrin receptor, insulin receptor, IGF-I and IGF-II receptors, among others. Also provided are pharmaceutical compositions and methods for administering the drugs to a subject in need by means of the receptor-targeted immunoliposomes.
Chief Brain Physiology Metabolism Section At National Institute On Aging, National Institutes Of Health
Position:
Chief Brain Physiology Metabolism Section at National Institute on Aging, National Institutes of Health
Location:
Washington D.C. Metro Area
Industry:
Research
Work:
National Institute on Aging, National Institutes of Health
-
Chief Brain Physiology Metabolism Section
Method For Treating Cognitive Disorders With Phenserine
US Patent:
5409948, Apr 25, 1995
Filed:
Nov 23, 1992
Appl. No.:
7/980399
Inventors:
Nigel H. Greig - Silver Spring MD
Arnold Brossi - Bethesda MD
Timothy T. Soncrant - Silver Spring MD
Harold W. Holloway - Bethesda MD
Stanley I. Rapoport - Washington DC
Setsu Iijima - Tokyo, JP
Edward L. Spangler - Baltimore MD
Donald K. Ingram - Ellicott City MD
Xue F. Pei - Bethesda MD
Arnold Brossi - Bethesda MD
Timothy T. Soncrant - Silver Spring MD
Harold W. Holloway - Bethesda MD
Stanley I. Rapoport - Washington DC
Setsu Iijima - Tokyo, JP
Edward L. Spangler - Baltimore MD
Donald K. Ingram - Ellicott City MD
Xue F. Pei - Bethesda MD
Assignee:
The United States of America as represented by the Secretary of the
Department of Health and Human Services - Washington DC
Department of Health and Human Services - Washington DC
International Classification:
A61K 3140
US Classification:
514411
Abstract:
An improved method of cholinomimetic therapy for cognitive impairments associated with aging and Alzheimer's disease comprising treating a patient with an effective amount of phenserine or a pharmaceutically acceptable salt and derivatives.
Substituted Phenserines As Specific Inhibitors Of Acetylcholinesterase
US Patent:
5171750, Dec 15, 1992
Filed:
Sep 26, 1991
Appl. No.:
7/765746
Inventors:
Arnold Brossi - Bethesda MD
Malgarzota Brzostowska - Poznan, PL
Stanley I. Rapoport - Washington DC
Nigel Greig - Silver Spring MD
Malgarzota Brzostowska - Poznan, PL
Stanley I. Rapoport - Washington DC
Nigel Greig - Silver Spring MD
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
and Human Services - Washington DC
International Classification:
A61K 3140, C07D491048
US Classification:
514411
Abstract:
The present invention relates to substituted phenylcarbamate or naphthylcarbamate tricyclic compounds which provide highly potent and selective cholinergic agonist and blocking activity and their use as pharmaceutical agents. The invention further relates to improvements in therapy relative to cholinergic diseases such as glacuoma, Myasthenia Gravis, Alzheimer's disease and to improvements in therapy and organophosphate poisoning. The invention further provides for a selective acetylcholinesterase and butyrylcholinesterase agents and a method for inhibiting these esterases.
Carbamates Related To (-)-Physostigmine As Cholinergic Agents
US Patent:
4900748, Feb 13, 1990
Filed:
Mar 4, 1988
Appl. No.:
7/166825
Inventors:
Arnold Brossi - Bethesda MD
John R. Atack - Bethesda MD
Stanley I. Rapoport - Washington DC
John R. Atack - Bethesda MD
Stanley I. Rapoport - Washington DC
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
and Human Services - Washington DC
International Classification:
A61K 3140, C07D48700
US Classification:
514411
Abstract:
Highly potent analogs of (-)-physostigmine are provided which are potent inhibitors of acetylcholinesterase and butyrylcholinesterase. These compounds are useful in treatment of glaucoma, Alzheimer's disease, myasthenia gravis, and organophosphate poisoning.
Enhancing Drug Delivery To The Brain
US Patent:
4835182, May 30, 1989
Filed:
Aug 21, 1987
Appl. No.:
7/088982
Inventors:
Nigel H. Greig - Washington DC
Daniel J. Sweeney - Indianapolis IN
Stanley I. Rapoport - Washington DC
Daniel J. Sweeney - Indianapolis IN
Stanley I. Rapoport - Washington DC
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
and Human Services - Washington DC
International Classification:
A61K 31245, C07C10164
US Classification:
514538
Abstract:
Tertiary butyl esters of anticancer drugs are provided which have the following formula: ##STR1## wherein R. sub. 1 and R. sub. 2 are the same or different and are selected from the group consisting of H, F, Cl, Br, and I and R. sub. 2 can also be NH. sub. 2 ;
R. sub. 3, R. sub. 4, and R. sub. 5 are the same or different and are selected from the group consisting of H, F, Cl, Br, I, and C. sub. 1 -C. sub. 3 alkyl; wherein alkyl may be substituted with F, Cl, Br, or I, with the proviso that at least two of R. sub. 3, R. sub. 4, and R. sub. 5 are alkyl or substituted alkyl; and
n=0-4.
The compounds of the present invention can be used in treating cancer by significantly increasing the brain levels of the drugs of the invention and their active metabolites.
Synthesis Of Fluoroarachidonic Acid And Methods Of Use Thereof
US Patent:
2013030, Nov 14, 2013
Filed:
May 9, 2013
Appl. No.:
13/890884
Inventors:
Stanley I. Rapoport - Washington DC, US
Ameer Taha - Washington DC, US
Kishore Kotta - San Diego CA, US
Ameer Taha - Washington DC, US
Kishore Kotta - San Diego CA, US
International Classification:
A61K 51/04
US Classification:
424 189, 554 88, 554150, 554175
Abstract:
There are provided, inter alia, methods for diagnosis of the extent of neuroinflammation in a subject. The methods include administering an F-labeled arachidonic acid to a subject in need thereof, obtaining a positron emission tomography (PET) scan of the subject, and determine the extent of neuroinflammation from the PET scan. There are provided, inter alia, methods of synthesis of reagents useful for the production of an F-labeled arachidonic acid.